UNSPSC 51201575: Ixekizumab

Injectable medication for the treatment of autoimmune diseases. Chemically, it is a form of a humanized monoclonal antibody. The substance acts by binding interleukin 17A and neutralizing it, reducing inflammation

UNSPSC 51201575 Ixekizumab, a Commodity code, shows minimal relevant recent state and local procurement activity. The code nominally covers a biologic immunosuppressant used to treat inflammatory conditions including psoriasis and rheumatoid arthritis. The most recent opportunities posted against this code are administrative or unrelated notices—a county purchasing department relocation announcement, vendor networking events, and a survey—none of which represent actual procurement of the drug itself or closely related pharmaceuticals. Of the genuinely transactional solicitations in the source block, only one—Seminole County, Florida's ITQ for naloxone and drug deactivation systems (IFB60459723LAS, due July 26, 2023)—involves pharmaceutical procurement, but naloxone is an opioid antagonist used in emergency overdose response, not an immunosuppressant, making it categorically distinct from ixekizumab.

The source does not document any recent state or local agencies actively soliciting ixekizumab or closely analogous biologics. County health departments, fire departments, and forensic labs appear in the opportunities block, but their pharmaceutical buys target emergency medical supplies, opioid-response products, and drug-standards for laboratory analysis—not rheumatologic or dermatologic biologics. Geographic coverage across Florida, Texas, Arizona, Minnesota, and Arkansas reflects broad state and local procurement activity overall, but not concentration in ixekizumab or similar specialty pharmaceutical categories. Absent documented recent demand for this drug at the state and local level, the code warrants a watch posture pending evidence of agency interest in biologic immunosuppressants for employee health plans, public health clinics, or corrections health services.